Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine

Vaccine

Volumn 24, Issue 21, 2006, Pages 4524-4526

  Bråve, Andreas ^a,b   Ljungberg, Karl ^c   Boberg, Andreas ^a,b   Rollman, Erik ^a,b   Engström, Gunnel ^a   Hinkula, Jorma ^a,b   Wahren, Britta ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

DNA vaccination; HIV 1; Multivalent vaccine

Indexed keywords

GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; GENE DELIVERY SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AIDS VACCINES; ANIMALS; GENES, VIRAL; HIV-1; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMIDS;

EID: 33646847847     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.018     Document Type: Article

References (9)

1. Diez-Delgado J., Dal-Re R., Llorente M., Gonzalez A., and Lopez J. Hepatitis B component does not interfere with the immune response to diphtheria, tetanus and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants. Vaccine 15 12-13 (1997) 1418-1422
2. Daum R.S., Zenko C.E., Given G.Z., Ballanco G.A., Parikh H., and Germino K. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J Infect Dis 184 10 (2001) 1293-1299
3. Leung L., Srivastava I.K., Kan E., et al. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. Aids 18 7 (2004) 991-1001
4. Sedegah M., Charoenvit Y., Aguiar J., et al. Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun 5 7 (2004) 553-561
5. Bråve A., Ljungberg K., Rollman E., and Wahren B. Multisubtype/multigene DNA immunization against HIV. Rational design of vaccines and immunotherapeutics (2004), Keystone, Colorado, USA
6. Zuber A.K., Bråve A., Engström G., et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 22 13-14 (2004) 1791-1798
7. Isaguliants M.G., Petrakova N.N., Zuber B., et al. DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge. Intervirology 43 4-6 (2000) 288-293
8. Ljungberg K., Rollman E., Eriksson L., Hinkula J., and Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 302 1 (2002) 44-57
9. Kjerrström A., Hinkula J., Engström G., et al. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 284 1 (2001) 46-61